IcyAlchemist
2021-11-30
Like and comment
ImmunoGen Stock Soars On Positive Data From Ovarian Cancer Drug Trial<blockquote>卵巢癌药物试验的积极数据使免疫原股价飙升</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":609675925,"tweetId":"609675925","gmtCreate":1638283546171,"gmtModify":1638283546291,"author":{"id":3586429646894350,"idStr":"3586429646894350","authorId":3586429646894350,"authorIdStr":"3586429646894350","name":"IcyAlchemist","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":21,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like and comment</p></body></html>","htmlText":"<html><head></head><body><p>Like and comment</p></body></html>","text":"Like and comment","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/609675925","repostId":1174359019,"repostType":4,"repost":{"id":"1174359019","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638282153,"share":"https://www.laohu8.com/m/news/1174359019?lang=zh_CN&edition=full","pubTime":"2021-11-30 22:22","market":"us","language":"en","title":"ImmunoGen Stock Soars On Positive Data From Ovarian Cancer Drug Trial<blockquote>卵巢癌药物试验的积极数据使免疫原股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1174359019","media":"Tiger Newspress","summary":"ImmunoGen shares soared 46% Tuesday after the cancer drug specialists said its ovarian cancer treatm","content":"<p>ImmunoGen shares soared 46% Tuesday after the cancer drug specialists said its ovarian cancer treatment met the primary goals of a late-stage study.</p><p><blockquote>癌症药物专家表示其卵巢癌治疗达到了后期研究的主要目标后，ImmunoGen股价周二飙升46%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/77ef54f585fc3671ff475aa8ed50d2be\" tg-width=\"850\" tg-height=\"819\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> ImmunoGen said mirvetuximab, its treatment for patients with platinum-resistant ovarian cancer, performed well in a pivotal SORAYA trial. Mirvetuximab had a confirmed objective response rate (ORR) of 32.4%, the drugmaker said, with a duration of response of 5.9 months in the 106-person trial.</p><p><blockquote>ImmunoGen表示，其治疗铂类耐药卵巢癌患者的mirvetuximab在一项关键的SORAYA试验中表现良好。该制药商表示，mirvetuximab的确认客观缓解率（ORR）为32.4%，在106人的试验中，缓解持续时间为5.9个月。</blockquote></p><p> ImmunoGen said the data would be submitted to the U.S. Food & Drug Administration as party of the agency's' Biologics License Application process in the first quarter of next year.</p><p><blockquote>ImmunoGen表示，这些数据将于明年第一季度作为该机构生物制品许可证申请流程的一部分提交给美国食品和药物管理局。</blockquote></p><p> \"This is an exciting moment, both for the field of ovarian cancer and for ImmunoGen, and the outcomes from SORAYA further validate our longstanding history of innovation in ADCs,\" said ECEO Mark Enyedy. \"We are moving forward expeditiously to complete the BLA for mirvetuximab, with the goal of submitting the application to FDA for accelerated approval in the first quarter of 2022. In parallel, commercial preparations are well underway to support the potential launch of mirvetuximab next year.\"</p><p><blockquote>ECEO Mark Enyedy表示：“对于卵巢癌领域和免疫原来说，这都是一个激动人心的时刻，SORAYA的结果进一步验证了我们在ADC方面悠久的创新历史。”“我们正在迅速完成mirvetuximab的BLA，目标是在2022年第一季度向FDA提交申请以获得加速批准。与此同时，商业准备工作正在顺利进行，以支持mirvetuximab明年的潜在上市。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunoGen Stock Soars On Positive Data From Ovarian Cancer Drug Trial<blockquote>卵巢癌药物试验的积极数据使免疫原股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunoGen Stock Soars On Positive Data From Ovarian Cancer Drug Trial<blockquote>卵巢癌药物试验的积极数据使免疫原股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-30 22:22</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>ImmunoGen shares soared 46% Tuesday after the cancer drug specialists said its ovarian cancer treatment met the primary goals of a late-stage study.</p><p><blockquote>癌症药物专家表示其卵巢癌治疗达到了后期研究的主要目标后，ImmunoGen股价周二飙升46%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/77ef54f585fc3671ff475aa8ed50d2be\" tg-width=\"850\" tg-height=\"819\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> ImmunoGen said mirvetuximab, its treatment for patients with platinum-resistant ovarian cancer, performed well in a pivotal SORAYA trial. Mirvetuximab had a confirmed objective response rate (ORR) of 32.4%, the drugmaker said, with a duration of response of 5.9 months in the 106-person trial.</p><p><blockquote>ImmunoGen表示，其治疗铂类耐药卵巢癌患者的mirvetuximab在一项关键的SORAYA试验中表现良好。该制药商表示，mirvetuximab的确认客观缓解率（ORR）为32.4%，在106人的试验中，缓解持续时间为5.9个月。</blockquote></p><p> ImmunoGen said the data would be submitted to the U.S. Food & Drug Administration as party of the agency's' Biologics License Application process in the first quarter of next year.</p><p><blockquote>ImmunoGen表示，这些数据将于明年第一季度作为该机构生物制品许可证申请流程的一部分提交给美国食品和药物管理局。</blockquote></p><p> \"This is an exciting moment, both for the field of ovarian cancer and for ImmunoGen, and the outcomes from SORAYA further validate our longstanding history of innovation in ADCs,\" said ECEO Mark Enyedy. \"We are moving forward expeditiously to complete the BLA for mirvetuximab, with the goal of submitting the application to FDA for accelerated approval in the first quarter of 2022. In parallel, commercial preparations are well underway to support the potential launch of mirvetuximab next year.\"</p><p><blockquote>ECEO Mark Enyedy表示：“对于卵巢癌领域和免疫原来说，这都是一个激动人心的时刻，SORAYA的结果进一步验证了我们在ADC方面悠久的创新历史。”“我们正在迅速完成mirvetuximab的BLA，目标是在2022年第一季度向FDA提交申请以获得加速批准。与此同时，商业准备工作正在顺利进行，以支持mirvetuximab明年的潜在上市。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMGN":"ImmunoGen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174359019","content_text":"ImmunoGen shares soared 46% Tuesday after the cancer drug specialists said its ovarian cancer treatment met the primary goals of a late-stage study.\n\nImmunoGen said mirvetuximab, its treatment for patients with platinum-resistant ovarian cancer, performed well in a pivotal SORAYA trial. Mirvetuximab had a confirmed objective response rate (ORR) of 32.4%, the drugmaker said, with a duration of response of 5.9 months in the 106-person trial.\nImmunoGen said the data would be submitted to the U.S. Food & Drug Administration as party of the agency's' Biologics License Application process in the first quarter of next year.\n\"This is an exciting moment, both for the field of ovarian cancer and for ImmunoGen, and the outcomes from SORAYA further validate our longstanding history of innovation in ADCs,\" said ECEO Mark Enyedy. \"We are moving forward expeditiously to complete the BLA for mirvetuximab, with the goal of submitting the application to FDA for accelerated approval in the first quarter of 2022. In parallel, commercial preparations are well underway to support the potential launch of mirvetuximab next year.\"","news_type":1,"symbols_score_info":{"IMGN":0.9}},"isVote":1,"tweetType":1,"viewCount":679,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":14,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/609675925"}
精彩评论